Duquesne Family Office Portfolio in 2026: Top Holdings & Recent Changes
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Stanley Druckenmiller's Duquesne Family Office Q3 2025 portfolio showcases his legendary macro-driven trading prowess with explosive new bets in biotech and selective trims amid high turnover. The $4.1B portfolio reflects aggressive repositioning, including massive additions to healthcare innovators while maintaining core tech exposure, signaling Druckenmiller's conviction in high-growth sectors despite market volatility.
Portfolio Snapshot: High Turnover, Biotech Heavy
Portfolio Highlights (Q3’2025): - Market Value: $4,062.0M - Top 10 Holdings: 53.9% - Portfolio Size: 65 -6 - Average Holding Period: 3 quarters - Turnover: 92.3%
The Duquesne Family Office portfolio maintains moderate concentration with the top 10 holdings commanding 53.9% of the $4.1 billion total, a hallmark of Druckenmiller's willingness to make bold, outsized bets when conviction is high. The portfolio shrank by 6 positions to 65, paired with an eye-watering 92.3% turnover rate, underscoring his short-term trading style rather than long-term buy-and-hold. The average holding period of just 3 quarters further highlights this dynamic approach, where positions are actively managed based on macro shifts and opportunity sets.
This quarter's moves reveal a pivot toward healthcare and growth names, with several multi-thousand percent additions signaling fresh opportunities Druckenmiller spotted in undervalued or breakout stories. While not ultra-concentrated like some peers, the 53.9% top-10 weighting shows disciplined focus amid the high turnover, allowing flexibility in a volatile market. Tracking the full Duquesne portfolio on ValueSense reveals how these changes align with broader sector rotations.
Druckenmiller's strategy here emphasizes agility: trimming laggards aggressively while piling into perceived inflection points, a pattern consistent with his macro expertise honed over decades.
Top Positions Breakdown: Biotech Bets Dominate New Buys
Duquesne's portfolio leads with a staggering Natera, Inc. (NTRA) at 12.7% after an explosive Add 2,707.45%, building to $517.4M across 3.2 million shares. Close behind is Insmed Incorporated (INSM) (8.6%, $349.0M), boosted by Add 2,323.44%, highlighting biotech conviction. Teva Pharmaceutical Industries Limited (TEVA) (8.3%, $335.2M) saw a modest Add 3.91% on 16.6 million shares, rounding out the healthcare surge.
The core holds steady with Taiwan Semiconductor Manufacturing Company Limited (TSM) at 5.3% $213.7M on No change, providing semiconductor stability. Woodward, Inc. (WWD) (3.9%, $160.0M) faced Reduce 25.43%, signaling profit-taking. Additions continued with Coupang, Inc. (CPNG) (3.7%, $149.2M, Add 12.85%), MercadoLibre, Inc. (MELI) (3.4%, $136.3M, Add 8.60%), and DocuSign, Inc. (DOCU) (3.0%, $121.5M, Add 30.65%).
Further changes include Ishares Tr (2.5%, $101.5M, Reduce 53.26%), Amazon.com, Inc. (AMZN) (2.4%, $96.0M, Add 219.58%), and Roku, Inc. (ROKU) (2.0%, $82.4M, Reduce 25.27%). Stable names like Verona Pharma Plc (2.6%, $106.9M, No change) add balance, painting a picture of aggressive growth hunting across biotech, e-commerce, and tech.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
What Druckenmiller's Moves Reveal About His Macro Playbook
Druckenmiller's Q3 actions spotlight a biotech and healthcare overweight, with NTRA, INSM, and TEVA comprising over 29% combined—massive new bets on innovative therapies amid sector undervaluation. This suggests optimism for drug pipelines and recovery plays in a post-rate-cut environment.
Global growth exposure shines through TSM, MELI, and CPNG, blending semiconductors and emerging market e-commerce for diversified upside. Reductions in WWD, ROKU, and Ishares Tr indicate risk management, shedding cyclical industrials and streaming amid competitive pressures.
High turnover 92.3% underscores a tactical, macro-responsive style, prioritizing inflection points over permanence. No heavy dividend focus; instead, it's growth-at-reasonable-prices with geographic tilt toward U.S., Asia, and LatAm.
Portfolio Concentration Analysis
| Position | Value | % of Portfolio | Recent Change |
|---|---|---|---|
| Natera, Inc. | $517.4M | 12.7% | Add 2,707.45% |
| Insmed Incorporated | $349.0M | 8.6% | Add 2,323.44% |
| Teva Pharmaceutical Industries Limited | $335.2M | 8.3% | Add 3.91% |
| Taiwan Semiconductor Manufacturing Company Limited | $213.7M | 5.3% | No change |
| Woodward, Inc. | $160.0M | 3.9% | Reduce 25.43% |
| Coupang, Inc. | $149.2M | 3.7% | Add 12.85% |
| MercadoLibre, Inc. | $136.3M | 3.4% | Add 8.60% |
| DocuSign, Inc. | $121.5M | 3.0% | Add 30.65% |
| Verona Pharma Plc | $106.9M | 2.6% | No change |
| Ishares Tr | $101.5M | 2.5% | Reduce 53.26% |
This table crystallizes Duquesne's focused firepower: the top three holdings alone—NTRA, INSM, TEVA—grab 29.6%, with biotech dominating new capital deployment. The 53.9% top-10 slice shows conviction without over-reliance on any single name, balancing moonshot adds (e.g., NTRA's 2,707% surge) against trims like Ishares Tr's 53% cut.
Such concentration amplifies returns potential in winners but demands precise timing, aligning with Druckenmiller's track record of macro bets. The mix of No change holds like TSM provides anchors amid the churn.
Investment Lessons from Stanley Druckenmiller's Approach
- Embrace high-conviction macro bets: Massive adds like NTRA 2,707% show sizing up when global trends align with undervalued growth.
- High turnover isn't speculation—it's adaptability: 92.3% churn reflects constant reassessment, cutting losers (ROKU -25%) to fund winners.
- Sector rotation over diversification: Pivot to biotech/healthcare signals reading economic inflections others miss.
- Short holding periods demand discipline: 3-quarter average means exiting on thesis change, not hope.
- Balance growth with global exposure: TSM and MELI pair U.S. biotech with Asia/LatAm for risk-spread.
Looking Ahead: What Comes Next?
With portfolio size down to 65 -6 and sky-high turnover, Duquesne likely holds dry powder for opportunistic strikes, especially if biotech momentum builds post-earnings. Current positioning—healthcare heavy with tech anchors—sets up well for AI/semiconductor tailwinds (TSM) and e-commerce recovery (CPNG, MELI).
Watch for volatility in rates or geopolitics prompting further trims/adds; Druckenmiller's style thrives in uncertainty, potentially targeting undervalued AI adjacencies or energy if macros shift. The Duquesne Family Office portfolio remains primed for asymmetric upside.
FAQ about Duquesne Family Office Portfolio
Q: What are the biggest changes in Duquesne's Q3 2025 13F filing?
A: Massive biotech initiations dominate: NTRA (Add 2,707.45%, now 12.7%) and INSM (Add 2,323.44%, 8.6%), plus trims like Ishares Tr (Reduce 53.26%).
Q: Why is Duquesne's portfolio turnover so high at 92.3%?
A: Druckenmiller's tactical style prioritizes macro shifts over long holds; average 3-quarter period allows quick pivots to high-conviction ideas like biotech, avoiding stagnation.
Q: What sectors does Duquesne favor now?
A: Heavy biotech/healthcare (NTRA, INSM, TEVA ~29%), with tech semis (TSM) and e-commerce (CPNG, MELI) for growth balance.
Q: How can retail investors track Duquesne like a pro?
A: Use ValueSense's superinvestor tracker at https://valuesense.io/superinvestors/duquesnefamily for real-time 13F updates (note 45-day lag), intrinsic values, and alerts on changes.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2026)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!